Evidence map›Paper›PMID 38070115›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Genetic Modification of Tumor-Infiltrating Lymphocytes, Peripheral T Cells, and T-Cell Model Cell Lines.

Hadas Weinstein-Marom, Dayana Blokon-Kogan, Maya Levi-Mann, Chaja Katzman, Shira Shalev, Masha Zaitsev, Michal J Besser, Ronnie Shapira-Frommer, Gideon Gross, Orit Itzhaki and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hadas Weinstein-MaromLaboratory of Immunology, MIGAL - Galilee Research Institute, Kiryat Shmona, Israel.
Dayana Blokon-KoganLaboratory of Immunology, MIGAL - Galilee Research Institute, Kiryat Shmona, Israel.
Maya Levi-MannLaboratory of Immunology, MIGAL - Galilee Research Institute, Kiryat Shmona, Israel.
Chaja KatzmanFaculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel.
Shira ShalevFaculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel.
Masha ZaitsevFaculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel.
Michal J BesserElla Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
Ronnie Shapira-FrommerElla Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
Gideon GrossLaboratory of Immunology, MIGAL - Galilee Research Institute, Kiryat Shmona, Israel.
Orit ItzhakiElla Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
Lior NissimFaculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel. lior.nissim@mail.huji.ac.il.
Hebrew University of Jerusalem · ILMigal - Galilee Technology Center · ILSheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic modification of tumor-infiltrating lymphocytes (TILs) or circulating T cells has become an important avenue in cancer therapy. Here we describe a comprehensive method for establishing and expanding TIL cultures and genetically modifying them with a gene of interest (GOI) via retroviral transduction or mRNA transfection. The method includes all the important steps starting with TIL extraction from tumors through to the maintenance of the genetically modified TILs. The protocol includes instructions for retroviral transduction and mRNA transfection of circulating T cells or T-cell lines. The GOIs most commonly introduced into the target cells are chimeric antigen receptors (CARs); genetic adjuvants, such as membrane-bound interleukins; and antitumor T-cell receptors (TCRs).

Indexed as

Lymphocytes, Tumor-InfiltratingT-LymphocytesCD8-Positive T-LymphocytesCell LineImmunotherapy, AdoptiveReceptors, Antigen, T-CellRNA, MessengerTransfectionReceptors, Antigen, T-CellRNA, MessengerAdoptive cell therapyCD8 T cellsChimeric antigen receptorsmRNA electroporationPreparation of T cellsRapid expansion protocolRetroviral transductionT cell activationTumor-infiltrating lymphocyte

Identifiers

PMID38070115
OpenAlexW4389507862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.